Newsletter Tool

Weekly Digest

This Week

Mar 14, 2025

NIH still terminating research grants, defying federal orders: Boston Globe

Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment

Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide

NIH unveils plan to centralize grant reviews in effort to save $65M-plus annually

Nasdaq stock market plans move to 24-hour trading in US

Bayer CEO Bill Anderson took pay cut in 2024 as company kicked off 3-year restructuring

Dexcom receives FDA warning letter over CGM manufacturing issues

Featured

NIH still terminating research grants, defying federal orders: Boston Globe

By Gabrielle Masson

In defiance of federal orders, the National Institutes of Health is still terminating grants to researchers across the country, The Boston Globe reports.

Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment

By Angus Liu

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma bought for $4.3 billion in 2019.

Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide

By Kevin Dunleavy

A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

NIH unveils plan to centralize grant reviews in effort to save $65M-plus annually

By Darren Incorvaia

The National Institutes of Health unveiled a plan on March 6 to move the peer review of grant applications, cooperative agreements and research and development contracts to a central location at the agency’s Center for Scientific Review.

Nasdaq stock market plans move to 24-hour trading in US

By Gabrielle Masson

Nasdaq plans to roll out 24-hour trading for U.S. companies in a move designed to modernize the market.

Bayer CEO Bill Anderson took pay cut in 2024 as company kicked off 3-year restructuring

By Fraiser Kansteiner

In 2024, Bayer chief Bill Anderson’s total compensation fell about 21% to 8.84 million euros ($9.6 million). The decline shouldn’t come as a total shock, given that 3.8 million euros of Anderson’s 2023 pay package came from a one-time "indemnity payment" he received after leaving Roche.

Novo Nordisk links CagriSema to 16% weight loss, sending stock down again

By Nick Paul Taylor

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen even further short of that bar in the second study.

Dexcom receives FDA warning letter over CGM manufacturing issues

By Conor Hale

Dexcom has received a warning letter from the FDA, following two inspections of the diabetes tech company's facilities last year.

GSK, Novartis, Lilly among Big Pharmas celebrating International Women’s Day 2025

By Andrea Park

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts and drumming up greater awareness and support for the ongoing movement toward gender equality.

Merck opens $1B Gardasil manufacturing facility in North Carolina

By Kevin Dunleavy

At its sprawling manufacturing complex in Durham, N.C., Merck has opened a new $1 billion plant slated to produce megablockbuster HPV vaccine Gardasil.

Fierce podcasts

Don’t miss an episode

Ways providers can simplify patient billing

Some health tech companies help providers communicate more proactively with patients about what they might owe and what repayment options are available to them.

What’s next for digital health investing in 2025?

Research reveals ‘ticking DNA clock’ behind Huntington’s disease

AI, AI & more AI: The biggest topics from ViVE 2025

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper